<code id='8A2868F464'></code><style id='8A2868F464'></style>
    • <acronym id='8A2868F464'></acronym>
      <center id='8A2868F464'><center id='8A2868F464'><tfoot id='8A2868F464'></tfoot></center><abbr id='8A2868F464'><dir id='8A2868F464'><tfoot id='8A2868F464'></tfoot><noframes id='8A2868F464'>

    • <optgroup id='8A2868F464'><strike id='8A2868F464'><sup id='8A2868F464'></sup></strike><code id='8A2868F464'></code></optgroup>
        1. <b id='8A2868F464'><label id='8A2868F464'><select id='8A2868F464'><dt id='8A2868F464'><span id='8A2868F464'></span></dt></select></label></b><u id='8A2868F464'></u>
          <i id='8A2868F464'><strike id='8A2868F464'><tt id='8A2868F464'><pre id='8A2868F464'></pre></tt></strike></i>

          entertainment

          entertainment

          author:entertainment    Page View:481

          What does it mean to a bad CEO? Can biotech endure another election year? And can you go to too many J.P. Morgan parties?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our last episode of 2023, so we look back on the biggest stories of the year, discuss the best and worst CEOs in the industry, and make some reasonably informed guesses on what 2024 has in store for the drug industry.

          advertisement

          For more on what we cover, here are the year’s best CEOs; here are the worst; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          Listen: Who gets the credit for GLP
          Listen: Who gets the credit for GLP

          Whenisnegativedatapositiveenough?Whogetscreditforscientificbreakthroughs?Andwasn’tbiotechsupposedtob

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Medicaid, Medicare dual

          TheSenatehassetitseyesonregulatinginsuranceplansforsomeofthemostvulnerablepatientsintheU.S.— the12.5